PD-(L)1 x VEGF bispecifics prove a big draw.
ApexOnco Front Page
Recent articles
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
But the timeline for a US green light is less clear, and the group has a cash crisis.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
